Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Somlo

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survivalG Somlo, J H Doroshow, S J Forman, et al.
Breast Cancer Research and Treatment|December 28, 2011
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivoB Ramaswamy, W Fiskus, B Cohen, et al.
Bone Marrow Transplantation|January 10, 2002
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancerR J Morgan, J H Doroshow, L Leong, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 7, 2012
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancerA VanderWalde, W Ye, P Frankel, et al.
Leukemia|November 28, 2012
Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignanciesA M Vanderwalde, C-L Sun, L Laddaran, et al.
Bone Marrow Transplantation|March 28, 2006
Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myelomaF Sahebi, R Spielberger, N M Kogut, et al.
Blood|March 1, 1997
Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancerG Somlo, I Sniecinski, T Odom-Maryon, et al.
Leukemia|July 29, 2000
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remissionA S Stein, M R O'Donnell, M L Slovak, et al.
Cancer Chemotherapy and Pharmacology|December 29, 2000
A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine AJ W Raschko, T W Synold, W Chow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell supportR J Morgan, J H Doroshow, K Venkataraman, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survivalG Somlo, J H Doroshow, S J Forman, et al.
Breast Cancer Research and Treatment|December 28, 2011
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivoB Ramaswamy, W Fiskus, B Cohen, et al.
Bone Marrow Transplantation|January 10, 2002
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancerR J Morgan, J H Doroshow, L Leong, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 7, 2012
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancerA VanderWalde, W Ye, P Frankel, et al.
Leukemia|November 28, 2012
Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignanciesA M Vanderwalde, C-L Sun, L Laddaran, et al.
Bone Marrow Transplantation|March 28, 2006
Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myelomaF Sahebi, R Spielberger, N M Kogut, et al.
Blood|March 1, 1997
Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancerG Somlo, I Sniecinski, T Odom-Maryon, et al.
Leukemia|July 29, 2000
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remissionA S Stein, M R O'Donnell, M L Slovak, et al.
Cancer Chemotherapy and Pharmacology|December 29, 2000
A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine AJ W Raschko, T W Synold, W Chow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell supportR J Morgan, J H Doroshow, K Venkataraman, et al.
Pageof 7